Remote Biometric Monitoring of Patients With COVID-19 With Exertional Hypoxia Treated With Supplemental Oxygen.

"Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: S. C. W. reports service as co-chair of the American College of Chest Physicians Clinical Practice Guideline: Antithrombotic therapy for venous thromboembolic disease. H. L. C. reports that the Sean N. Parker Center for Allergy & Asthma at Stanford University sponsored a portion of his research time for COVID-19 specific research. I.D.P. reports grant support from the 10.13039/100000002National Institutes of Health, 10.13039/100000030Centers for Disease Control and Prevention, and 10.13039/100008897Janssen Pharmaceuticals and support to his institution from Regeneron and Asahi Kasei Pharma. None declared (K. P., A. D., J. D., J. R. J., R. R., M. S., B. W., J. R. B.). AcknowledgmentsAuthor contributions: J. R. B. and H. L. C. are the guarantors of all content of this article. The authors participated in the following elements of the article: acquisition of data: H. L. C., I. D. P., J. D., J. R. J.; analysis of data: H. L. C., I. D. P.; interpretation of data: H. L. C., I. D. P., J. R. B.; drafting of manuscript: H. L. C., I. D. P., J. R. B., S. C. W.; critical revision of the manuscript: all authors; obtaining funding: H. L. C., I. D. P.Other contributions: The authors thank David Hasleton, MD, and the Intermountain Healthcare Emergency Department Executive team, Intermountain Healthcare Emergency Medicine, and Mike Lyons, BS, and Lory Maddox, PhD, RN, of Intermountain Healthcare for assistance in data acquisition."

"The authors have reported to CHEST the following: S. C. W. reports service as co-chair of the American College of Chest Physicians Clinical Practice Guideline: Antithrombotic therapy for venous thromboembolic disease. H. L. C. reports that the Sean N. Parker Center for Allergy & Asthma at Stanford University sponsored a portion of his research time for COVID-19 specific research. I.D.P. reports grant support from the 10.13039/100000002National Institutes of Health, 10.13039/100000030Centers for Disease Control and Prevention, and 10.13039/100008897Janssen Pharmaceuticals and support to his institution from Regeneron and Asahi Kasei Pharma. None declared (K. P., A. D., J. D., J. R. J., R. R., M. S., B. W., J. R. B.)."